RCS - Arecor Therapeutics - Arecor to present at Oppenheimer conference

Arecor TherapeuticsAnnouncement

09/03/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260309:nRSI7348Va&default-theme=true

RNS Number : 7348V  Arecor Therapeutics PLC  09 March 2026

 

Arecor Therapeutics plc

("Arecor" or the "Company")

 

Arecor to present at Oppenheimer Annual Healthcare MedTech & Services
Conference

Cambridge, UK, 9 March 2026: Arecor Therapeutics plc (AIM: AREC), a clinical
stage biotech company developing superior therapeutics that can reduce
treatment burden and improve outcomes for people living with diabetes, obesity
and other cardiometabolic diseases, will be presenting at the Oppenheimer
36(th) Annual Healthcare MedTech and Services Conference on 16 March. The
Arecor team will also be attending the Advanced Technologies & Treatments
for Diabetes (ATTD) conference, from 11-14 March. Full details for both events
are below:

 

Oppenheimer 36th Annual Healthcare MedTech & Services Conference - 16-19
March 2026, online

Sarah Howell will be presenting on Arecor's lead programme AT278, the only
ultra-concentrated, ultra-rapid acting insulin, designed to lower patient
burden and improve outcomes for people with diabetes in combination with
Automated Insulin Delivery (AID) Systems, at the Oppenheimer conference on
March 16, 2026 at 9.20am EDT. Click here
(https://event.summitcast.com/view/2MZVg3DCx8a3zxe3mMMekq/84b64yTGZjKwQQHr4cJQGd)
to register to watch the presentation.  The presentation will also be made
available on Arecor's website here (https://arecor.com/news/) after the event.
David Ellam, CFO, will also be attending.

 

Advanced Technologies & Treatments for Diabetes (ATTD) - 11-14 March 2026,
Barcelona

Sarah Howell (CEO), Jan Jezek (CSO) and David Gerring (CDO) will also be
attending ATTD 2026. The conference brings clinicians, diabetes care
providers, researchers, industry, investors, reimbursement authorities, and
regulators together in order to collaborate to drive rapid progress in
diabetes care.

 

For attendees at either conference interested in meeting the Arecor team,
please email BD@arecor.com.

-ENDS-

For more information, please contact:

 

 Arecor Therapeutics plc                          +44 (0) 1223 426060

Dr Sarah Howell, Chief Executive Officer

David Ellam, Chief Financial Officer            info@arecor.com

 Singer Capital Markets Advisory LLP              +44 (0) 20 7496 3000

(NOMAD and Broker)
 Phil Davies, James Fischer

 Vigo Consulting (Financial Communications)       +44 (0) 20 7390 0230
 Melanie Toyne-Sewell, Rozi Morris

                                                  arecor@vigoconsulting.com

 Vida Strategic Partners (US Investor Relations)  +1 (415) 675-7401

 Stephanie Diaz                                   sdiaz@vidasp.com

 

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a clinical stage biotech company developing
superior therapeutics that can reduce treatment burden and improve outcomes
for people living with diabetes, obesity and other cardiometabolic diseases.

Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid
acting insulin, which enables disruptive drug delivery devices. It is being
co-developed with Sequel Med Tech, a company commercialising state-of-the art
insulin delivery devices. Arecor is also developing a novel oral delivery
platform for peptides with its first validation target a GLP-1 receptor
agonist.

The Company is quoted on AIM (AIM: AREC) and is based in Cambridge, UK. For
further details please see www.arecor.com (http://www.arecor.com/)

About AT278

AT278 is a novel proprietary formulation of an existing insulin, designed to
accelerate the absorption of insulin post injection even at very high
concentrations (500U/mL). With its best-in-class profile, it has the potential
to disrupt the market for insulin treatment as the first concentrated, yet
very rapid acting insulin for the growing population of people with diabetes
with high daily insulin needs as well as to act as a critical enabler in the
development of next-generation, miniaturised longer wear automated insulin
delivery (AID) systems.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAAKABNPBKDCNK



            Copyright 2019 Regulatory News Service, all rights reserved